recent trial results, said experts as quoted by news agency AFP. The initial testing of the nasal-spray version of the Covid-19 vaccine developed by Oxford University researchers and AstraZeneca Plc, on human beings did not yield the desired protection.
The University of Oxford, in an official statement, said that the antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing.
Also, it also showed that the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination, the statement said as quoted by Reuters.
The British trial enrolled 30 previously unvaccinated participants as well as 12 volunteers, who had previously received a standard two-dose vaccine course by injection.